Minerva Neurosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
36.2%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.20next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly78.2MTarget: Sufficient to complete Phase 3 trial and resubmit NDA
Confirmatory Phase 3 Trial Patient Enrollment MonthlyTarget: Approximately 380 patients across 40 global sites
Watch Items
- Roluperidone Phase 3 Trial Efficacy ReadoutTrigger: 12-week primary efficacy endpoint (PANSS Marder negative symptoms factor score)Action: Prepare topline data analysis and prepare for Tranche B warrant milestone funding of $40 million
- Warrant Liability Fair Value FluctuationsTrigger: Significant non-cash GAAP net loss impact (e.g., $109.4 million expense in Q1 2026)Action: Monitor non-GAAP adjusted net loss metrics to assess underlying operational cash burn
Research as of 20 Jun 2026